BIOMAT Database Logo BIOMAT Database Logo

Treatment of diffuse aggressive non-Hodgkin's lymphomas with an intensive multi-drug regimen including high-dose cytosine arabinoside (F-MACHOP). 1985

S Amadori, and C Guglielmi, and A P Anselmo, and G Cimino, and L P Ruco, and G Papa, and C Biagini, and F Mandelli

UI MeSH Term Description Entries
D008223 Lymphoma A general term for various neoplastic diseases of the lymphoid tissue. Germinoblastoma,Lymphoma, Malignant,Reticulolymphosarcoma,Sarcoma, Germinoblastic,Germinoblastic Sarcoma,Germinoblastic Sarcomas,Germinoblastomas,Lymphomas,Lymphomas, Malignant,Malignant Lymphoma,Malignant Lymphomas,Reticulolymphosarcomas,Sarcomas, Germinoblastic
D008297 Male Males
D008727 Methotrexate An antineoplastic antimetabolite with immunosuppressant properties. It is an inhibitor of TETRAHYDROFOLATE DEHYDROGENASE and prevents the formation of tetrahydrofolate, necessary for synthesis of thymidylate, an essential component of DNA. Amethopterin,Methotrexate Hydrate,Methotrexate Sodium,Methotrexate, (D)-Isomer,Methotrexate, (DL)-Isomer,Methotrexate, Dicesium Salt,Methotrexate, Disodium Salt,Methotrexate, Sodium Salt,Mexate,Dicesium Salt Methotrexate,Hydrate, Methotrexate,Sodium, Methotrexate
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009367 Neoplasm Staging Methods which attempt to express in replicable terms the extent of the neoplasm in the patient. Cancer Staging,Staging, Neoplasm,Tumor Staging,TNM Classification,TNM Staging,TNM Staging System,Classification, TNM,Classifications, TNM,Staging System, TNM,Staging Systems, TNM,Staging, Cancer,Staging, TNM,Staging, Tumor,System, TNM Staging,Systems, TNM Staging,TNM Classifications,TNM Staging Systems
D011241 Prednisone A synthetic anti-inflammatory glucocorticoid derived from CORTISONE. It is biologically inert and converted to PREDNISOLONE in the liver. Dehydrocortisone,delta-Cortisone,Apo-Prednisone,Cortan,Cortancyl,Cutason,Dacortin,Decortin,Decortisyl,Deltasone,Encorton,Encortone,Enkortolon,Kortancyl,Liquid Pred,Meticorten,Orasone,Panafcort,Panasol,Predni Tablinen,Prednidib,Predniment,Prednison Acsis,Prednison Galen,Prednison Hexal,Pronisone,Rectodelt,Sone,Sterapred,Ultracorten,Winpred,Acsis, Prednison
D011379 Prognosis A prediction of the probable outcome of a disease based on a individual's condition and the usual course of the disease as seen in similar situations. Prognostic Factor,Prognostic Factors,Factor, Prognostic,Factors, Prognostic,Prognoses
D012008 Recurrence The return of a sign, symptom, or disease after a remission. Recrudescence,Relapse,Recrudescences,Recurrences,Relapses
D003520 Cyclophosphamide Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the LIVER to form the active aldophosphamide. It has been used in the treatment of LYMPHOMA and LEUKEMIA. Its side effect, ALOPECIA, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer. (+,-)-2-(bis(2-Chloroethyl)amino)tetrahydro-2H-1,3,2-oxazaphosphorine 2-Oxide Monohydrate,B-518,Cyclophosphamide Anhydrous,Cyclophosphamide Monohydrate,Cyclophosphamide, (R)-Isomer,Cyclophosphamide, (S)-Isomer,Cyclophosphane,Cytophosphan,Cytophosphane,Cytoxan,Endoxan,NSC-26271,Neosar,Procytox,Sendoxan,B 518,B518,NSC 26271,NSC26271
D003561 Cytarabine A pyrimidine nucleoside analog that is used mainly in the treatment of leukemia, especially acute non-lymphoblastic leukemia. Cytarabine is an antimetabolite antineoplastic agent that inhibits the synthesis of DNA. Its actions are specific for the S phase of the cell cycle. It also has antiviral and immunosuppressant properties. (From Martindale, The Extra Pharmacopoeia, 30th ed, p472) Ara-C,Arabinofuranosylcytosine,Arabinosylcytosine,Cytosine Arabinoside,Aracytidine,Aracytine,Cytarabine Hydrochloride,Cytonal,Cytosar,Cytosar-U,beta-Ara C,Ara C,Arabinoside, Cytosine,Cytosar U,beta Ara C

Related Publications

S Amadori, and C Guglielmi, and A P Anselmo, and G Cimino, and L P Ruco, and G Papa, and C Biagini, and F Mandelli
MACOP-B vs F-MACHOP regimen in the treatment of high-grade non-Hodgkin's lymphomas.
February 1995, Leukemia & lymphoma,
S Amadori, and C Guglielmi, and A P Anselmo, and G Cimino, and L P Ruco, and G Papa, and C Biagini, and F Mandelli
The F-MACHOP regimen in the treatment of aggressive non-Hodgkin's lymphomas: a single center experience in 72 patients.
January 1996, Haematologica,
S Amadori, and C Guglielmi, and A P Anselmo, and G Cimino, and L P Ruco, and G Papa, and C Biagini, and F Mandelli
MACOP-B vs F-MACHOP in the treatment of high-grade non-Hodgkin's lymphomas.
January 1991, Leukemia,
S Amadori, and C Guglielmi, and A P Anselmo, and G Cimino, and L P Ruco, and G Papa, and C Biagini, and F Mandelli
High-dose cytosine arabinoside in non-Hodgkin's lymphoma.
November 1983, Journal of clinical oncology : official journal of the American Society of Clinical Oncology,
S Amadori, and C Guglielmi, and A P Anselmo, and G Cimino, and L P Ruco, and G Papa, and C Biagini, and F Mandelli
A pilot study of short-course, high-dose cytosine arabinoside, etoposide, and cisplatin in refractory, aggressive-histology, non-Hodgkin's lymphomas.
December 1989, American journal of clinical oncology,
S Amadori, and C Guglielmi, and A P Anselmo, and G Cimino, and L P Ruco, and G Papa, and C Biagini, and F Mandelli
High-dose cytosine arabinoside. Active agent in treatment of non-Hodgkin's lymphoma.
November 1984, The American journal of medicine,
S Amadori, and C Guglielmi, and A P Anselmo, and G Cimino, and L P Ruco, and G Papa, and C Biagini, and F Mandelli
The treatment of elderly patients with aggressive non-Hodgkin's lymphomas: feasibility and efficacy of an intensive multidrug regimen.
August 1996, Leukemia & lymphoma,
S Amadori, and C Guglielmi, and A P Anselmo, and G Cimino, and L P Ruco, and G Papa, and C Biagini, and F Mandelli
Intensive chemotherapy regimen in high-grade non Hodgkin's lymphomas.
April 1987, Tumori,
S Amadori, and C Guglielmi, and A P Anselmo, and G Cimino, and L P Ruco, and G Papa, and C Biagini, and F Mandelli
The use of high-dose cytosine arabinoside for non-Hodgkin's lymphoma.
June 1985, Seminars in oncology,
S Amadori, and C Guglielmi, and A P Anselmo, and G Cimino, and L P Ruco, and G Papa, and C Biagini, and F Mandelli
Diffuse aggressive lymphomas: a curable subset of non-Hodgkin's lymphomas.
December 1986, Seminars in oncology,
Copied contents to your clipboard!